69_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Selected_NN
Financial_NN
Data_NN
Our_FPP1
audited_JJ
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [PASS]
presented_VBN
in_PIN
British_JJ
pounds_NN
sterling_GER
and_CC
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
UK_NN
GAAP_NN
differs_VPRT
in_PIN
certain_JJ
respects_NN
from_PIN
US_FPP1
GAAP_NN
._.
A_DT
reconciliation_NOMZ
of_PIN
certain_JJ
amounts_NN
from_PIN
UK_NN
GAAP_NN
to_PIN
US_FPP1
GAAP_NN
,_,
as_RB
well_RB
as_IN
a_DT
summary_NN
of_PIN
principal_JJ
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
applicable_JJ
to_PIN
us_FPP1
,_,
are_VPRT [PASS]
presented_VBN
in_PIN
note_NN
27_CD
to_PIN
our_FPP1
audited_JJ
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
included_VBD
elsewhere_RB
in_PIN
this_DEMO
annual_JJ
report_NN
._.
The_DT
following_VBG
summary_NN
financial_JJ
data_NN
should_NEMD
be_VB [PASS]
read_VBN
in_PIN
conjunction_NOMZ
with_PIN
Operating_GER
and_PHC
Financial_NN
Review_NN
and_PHC
Prospects_NN
and_CC
our_FPP1
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
including_VBG [PRESP]
the_DT
notes_NN
thereto_RB
._.
The_DT
summary_NN
statement_NOMZ
of_PIN
income_NN
data_NN
set_VBN [WZPAST]
forth_RB
below_PLACE
for_PIN
the_DT
fiscal_JJ
years_NN
ended_VBN
30_CD
September_NN
2002_CD
,_,
2001_CD
,_,
2000_CD
,_,
1999_CD
and_CC
1998_CD
,_,
and_ANDC
the_DT
consolidated_JJ
balance_NN
sheet_NN
data_NN
at_PIN
30_CD
September_NN
2002_CD
,_,
2001_CD
,_,
2000_CD
,_,
1999_CD
and_CC
1998_CD
have_VPRT [PEAS]
been_VBN [PASS]
derived_VBN
from_PIN
our_FPP1
audited_JJ
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
but_CC
do_VPRT
not_XX0
,_,
however_CONJ
,_,
constitute_VPRT
our_FPP1
statutory_JJ
accounts_NN
within_PIN
the_DT
meaning_GER
of_PIN
Section_NOMZ
240_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
in_PIN
the_DT
United_NN
Kingdom_NN
._.
ii_FW
Under_IN
UK_NN
GAAP_NN
,_,
potentially_RB
dilutive_JJ
issuable_JJ
shares_NN
are_VPRT [SPAU] [PASS]
only_DWNT
included_VBN
in_PIN
the_DT
calculation_NOMZ
of_PIN
fully_AMP
diluted_VBN
earnings_GER
per_PIN
share_NN
if_COND
their_TPP3
issue_NN
would_PRMD
decrease_VB
net_JJ
profit_NN
per_PIN
share_NN
or_CC
increase_NN
net_JJ
loss_NN
per_PIN
share_NN
._.
Since_OSUB
the_DT
Group_NN
has_VPRT [PEAS]
reported_VBN [PUBV]
losses_NN
,_,
its_PIT
basic_JJ
and_CC
fully_AMP
diluted_JJ
loss_NN
per_PIN
share_NN
are_VPRT [BEMA]
therefore_CONJ
equal_PRED
._.
